 The vaccine candidate VSV-ZEBOV BPSC1001 has shown promising safety and efficacy in preventing Ebola Zaire infections in non-human primates NHP. Before it can be assessed in large Phase IIb3 trials in affected areas, safety data from phase 1 first-in-human trials are needed. To accelerate this process, the World Health Organization WHO has constituted a consortium of Clinical Research Centers in Switzerland, Germany, and Africa that will use similar protocols to collectively include roughly 250 volunteers, the sample size required to identify a 2-fold difference in anti-ZEBOV IgG antibody titers following immunization with 2 different doses of BPSC1001. 